Empagliflozin & Linagliptin Tablets – GLEMPION -L 25/5 Tablets

GLEMPION – L 25/5 Tablets – Comprehensive diabetes care for better health and improved quality of life.

GLEMPION – L 25/5 Tablets – The Dual combination of Empagliflozin & Linagliptin Tablets is designed for optimal management of Type 2 Diabetes Mellitus (T2DM) where Empagliflozin is a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, promoting glucose excretion and lowering blood sugar levels and Linagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances incretin hormone levels, stimulating insulin release and reducing glucagon secretion.

Key Benefits of Empagliflozin & Linagliptin Tablets – GLEMPION -L 25/5 Tablets
✅Dual Mechanism of Action: Combines Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP-4 inhibitor) to target blood sugar control through complementary pathways.
✅Cardio-Renal Protection: Empagliflozin offers cardiovascular and renal benefits, reducing risks in diabetic patients with comorbidities.
✅Convenient Once-Daily Dose: Simplifies diabetes management with effective glycemic control and enhanced patient compliance.

Recommended By Specialists:
👨‍⚕️Diabetologists – Mainly specialists specifically focused on the management of diabetes, and they prescribe medications to optimize blood sugar levels and prevent long-term complications associated with diabetes.
👨‍⚕️Cardiologists – Since Empagliflozin has cardiovascular benefits (such as reducing the risk of heart failure and cardiovascular events), cardiologists may recommend this medication for diabetic patients who also have heart disease or are at risk for heart-related issues.
👨‍⚕️General Practitioners (GPs) – As it often diagnose and treat Type 2 diabetes and may prescribe this combination therapy to patients who need a more effective way to manage blood sugar alongside lifestyle changes.

INDICATIONS:
✅Type 2 Diabetes Mellitus
✅Patients requiring combination therapy for enhanced glycemic control
✅Suitable for patients at high cardiovascular or renal risk